vs
Medpace Holdings, Inc.（MEDP）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是Medpace Holdings, Inc.的1.5倍（$1.0B vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs 2.4%，领先16.7%），Medpace Holdings, Inc.同比增速更快（32.0% vs 9.6%），越洋钻探自由现金流更多（$321.0M vs $188.1M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 16.9%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
MEDP vs RIG — 直观对比
营收规模更大
RIG
是对方的1.5倍
$708.5M
营收增速更快
MEDP
高出22.5%
9.6%
净利率更高
MEDP
高出16.7%
2.4%
自由现金流更多
RIG
多$132.9M
$188.1M
两年增速更快
MEDP
近两年复合增速
16.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $1.0B |
| 净利润 | $135.1M | $25.0M |
| 毛利率 | — | 42.0% |
| 营业利润率 | 21.6% | 23.0% |
| 净利率 | 19.1% | 2.4% |
| 营收同比 | 32.0% | 9.6% |
| 净利润同比 | 15.5% | 257.1% |
| 每股收益（稀释后） | $4.65 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRIG
| Q4 25 | $708.5M | $1.0B | ||
| Q3 25 | $659.9M | $1.0B | ||
| Q2 25 | $603.3M | $988.0M | ||
| Q1 25 | $558.6M | $906.0M | ||
| Q4 24 | $536.6M | $952.0M | ||
| Q3 24 | $533.3M | $948.0M | ||
| Q2 24 | $528.1M | $861.0M | ||
| Q1 24 | $511.0M | $763.0M |
净利润MEDPRIG
| Q4 25 | $135.1M | $25.0M | ||
| Q3 25 | $111.1M | $-1.9B | ||
| Q2 25 | $90.3M | $-938.0M | ||
| Q1 25 | $114.6M | $-79.0M | ||
| Q4 24 | $117.0M | $7.0M | ||
| Q3 24 | $96.4M | $-494.0M | ||
| Q2 24 | $88.4M | $-123.0M | ||
| Q1 24 | $102.6M | $98.0M |
毛利率MEDPRIG
| Q4 25 | — | 42.0% | ||
| Q3 25 | — | 43.2% | ||
| Q2 25 | — | 39.4% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 39.2% | ||
| Q3 24 | — | 40.6% | ||
| Q2 24 | — | 38.0% | ||
| Q1 24 | — | 31.5% |
营业利润率MEDPRIG
| Q4 25 | 21.6% | 23.0% | ||
| Q3 25 | 21.5% | -163.1% | ||
| Q2 25 | 20.9% | -97.6% | ||
| Q1 25 | 20.3% | 7.1% | ||
| Q4 24 | 23.4% | 13.7% | ||
| Q3 24 | 21.1% | -51.2% | ||
| Q2 24 | 19.9% | -6.9% | ||
| Q1 24 | 20.4% | -0.4% |
净利率MEDPRIG
| Q4 25 | 19.1% | 2.4% | ||
| Q3 25 | 16.8% | -187.1% | ||
| Q2 25 | 15.0% | -94.9% | ||
| Q1 25 | 20.5% | -8.7% | ||
| Q4 24 | 21.8% | 0.7% | ||
| Q3 24 | 18.1% | -52.1% | ||
| Q2 24 | 16.7% | -14.3% | ||
| Q1 24 | 20.1% | 12.8% |
每股收益（稀释后）MEDPRIG
| Q4 25 | $4.65 | $0.13 | ||
| Q3 25 | $3.86 | $-2.00 | ||
| Q2 25 | $3.10 | $-1.06 | ||
| Q1 25 | $3.67 | $-0.11 | ||
| Q4 24 | $3.67 | $-0.14 | ||
| Q3 24 | $3.01 | $-0.58 | ||
| Q2 24 | $2.75 | $-0.15 | ||
| Q1 24 | $3.20 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $620.0M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $459.1M | $8.1B |
| 总资产 | $2.0B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资MEDPRIG
| Q4 25 | $497.0M | $620.0M | ||
| Q3 25 | $285.4M | $833.0M | ||
| Q2 25 | $46.3M | $377.0M | ||
| Q1 25 | $441.4M | $263.0M | ||
| Q4 24 | $669.4M | $560.0M | ||
| Q3 24 | $656.9M | $435.0M | ||
| Q2 24 | $510.9M | $475.0M | ||
| Q1 24 | $407.0M | $446.0M |
总债务MEDPRIG
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.9B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $6.2B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $6.8B |
股东权益MEDPRIG
| Q4 25 | $459.1M | $8.1B | ||
| Q3 25 | $293.6M | $8.1B | ||
| Q2 25 | $172.4M | $9.4B | ||
| Q1 25 | $593.6M | $10.2B | ||
| Q4 24 | $825.5M | $10.3B | ||
| Q3 24 | $881.4M | $10.2B | ||
| Q2 24 | $763.6M | $10.7B | ||
| Q1 24 | $671.5M | $10.5B |
总资产MEDPRIG
| Q4 25 | $2.0B | $15.6B | ||
| Q3 25 | $1.8B | $16.2B | ||
| Q2 25 | $1.6B | $17.8B | ||
| Q1 25 | $1.9B | $19.0B | ||
| Q4 24 | $2.1B | $19.4B | ||
| Q3 24 | $2.1B | $19.5B | ||
| Q2 24 | $1.9B | $20.3B | ||
| Q1 24 | $1.8B | $19.9B |
负债/权益比MEDPRIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $321.0M |
| 自由现金流率自由现金流/营收 | 26.6% | 30.8% |
| 资本支出强度资本支出/营收 | 0.6% | 2.7% |
| 现金转化率经营现金流/净利润 | 1.43× | 13.96× |
| 过去12个月自由现金流最近4个季度 | $681.9M | $626.0M |
8季度趋势，按日历期对齐
经营现金流MEDPRIG
| Q4 25 | $192.7M | $349.0M | ||
| Q3 25 | $246.2M | $246.0M | ||
| Q2 25 | $148.5M | $128.0M | ||
| Q1 25 | $125.8M | $26.0M | ||
| Q4 24 | $190.7M | $206.0M | ||
| Q3 24 | $149.1M | $194.0M | ||
| Q2 24 | $116.4M | $133.0M | ||
| Q1 24 | $152.7M | $-86.0M |
自由现金流MEDPRIG
| Q4 25 | $188.1M | $321.0M | ||
| Q3 25 | $235.5M | $235.0M | ||
| Q2 25 | $142.4M | $104.0M | ||
| Q1 25 | $115.8M | $-34.0M | ||
| Q4 24 | $183.0M | $177.0M | ||
| Q3 24 | $138.5M | $136.0M | ||
| Q2 24 | $103.5M | $49.0M | ||
| Q1 24 | $147.2M | $-169.0M |
自由现金流率MEDPRIG
| Q4 25 | 26.6% | 30.8% | ||
| Q3 25 | 35.7% | 22.9% | ||
| Q2 25 | 23.6% | 10.5% | ||
| Q1 25 | 20.7% | -3.8% | ||
| Q4 24 | 34.1% | 18.6% | ||
| Q3 24 | 26.0% | 14.3% | ||
| Q2 24 | 19.6% | 5.7% | ||
| Q1 24 | 28.8% | -22.1% |
资本支出强度MEDPRIG
| Q4 25 | 0.6% | 2.7% | ||
| Q3 25 | 1.6% | 1.1% | ||
| Q2 25 | 1.0% | 2.4% | ||
| Q1 25 | 1.8% | 6.6% | ||
| Q4 24 | 1.4% | 3.0% | ||
| Q3 24 | 2.0% | 6.1% | ||
| Q2 24 | 2.4% | 9.8% | ||
| Q1 24 | 1.1% | 10.9% |
现金转化率MEDPRIG
| Q4 25 | 1.43× | 13.96× | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | 29.43× | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
